Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors
A year after Cirius Therapeutics’ lead NASH drug flopped in a large Phase IIb trial, the biotech’s chief business and financial officer Brian Farmer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
